This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study
by Zacks Equity Research
AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100
by Zacks Equity Research
Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
by Zacks Equity Research
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
by Zacks Equity Research
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
Royal Wedding In Focus
by Zacks Equity Research
Royal Wedding In Focus
Royal Wedding Stirs Interest in U.K. Stocks
by Mark Vickery
We thought it might be worthwhile to take a peek at the performance of British-oriented stocks.
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca (AZN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.
Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates
by Zacks Equity Research
Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.
Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View
by Ekta Bagri
Valeant's (VRX) first-quarter earnings topped estimates driven by growth in Bausch + Lomb/International segment and Salix businesses. The company also upped its view.
Inovio's (INO) Q1 Loss Wider than Expected, Shares Down
by Zacks Equity Research
Inovio (INO) reports wider-than-expected loss and revenues miss estimates in the first quarter of 2018.
Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.
Is a Beat in the Cards for Perrigo (PRGO) in Q1 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and introductions in the Rx segment might shoot up sales in the near future.
Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)
by Zacks Equity Research
Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
by Zacks Equity Research
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
Merck's Keytruda Reduces Death Risk in Melanoma Patients
by Zacks Equity Research
Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
by Zacks Equity Research
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy
by Zacks Equity Research
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
by Zacks Equity Research
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
Pfizer's Lung Cancer Candidate Gets FDA's Priority Review
by Zacks Equity Research
Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.
3 Emerging Technologies Set to Transform the Pharma World
by Kinjel Shah
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.